Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ligand Pharma ( (LGND) ) has provided an announcement.
On August 11, 2025, Ligand Pharmaceuticals announced a proposed offering of $400 million in convertible senior notes due 2030, aimed at qualified institutional buyers. This financial move is expected to support Ligand’s strategic initiatives, including potential repurchases of its common stock and investments in complementary businesses, which could influence the market dynamics of its stock and overall financial positioning.
The most recent analyst rating on (LGND) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.
Ligand Pharma’s overall stock score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance and valuation concerns, such as declining revenue and a negative P/E ratio, weigh down the score. Technical analysis shows bullish momentum, but caution is advised due to overbought signals.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
Ligand Pharmaceuticals Incorporated operates in the pharmaceutical industry, focusing on developing and acquiring technologies that aid in drug discovery and development. The company is known for its innovative solutions and partnerships with other biotech and pharmaceutical companies.
Average Trading Volume: 154,738
Technical Sentiment Signal: Buy
Current Market Cap: $2.9B
Learn more about LGND stock on TipRanks’ Stock Analysis page.